Ad Hoc | Novartis

Media Release
Jan 30, 2019
En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise
Media Release
Jan 30, 2019
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Media Release
Feb 25, 2019
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Media Release
Mar 14, 2019
Novartis announces change in Sandoz leadership
Media Release
Mar 22, 2019
Novartis plans for Alcon spin-off on April 9, 2019
Media Release
Mar 27, 2019
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Media Release
Jan 26, 2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Media Release
Feb 01, 2018
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
Media Release
Mar 12, 2018
Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques
Media Release
Mar 12, 2018
Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an
Media Release
Mar 12, 2018
Novartis announces changes to the Executive Committee to support strategic priorities
Media Release
Mar 27, 2018
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities